@OP+1jshwqt48, interesting point. In my opinion, this is an apples and oranges comparison. To be honest, more like an apple and a blue whale comparison. The 12/31/2024 Roche Balance Sheet “Cash on Hand” alone, is 4.5 times the total Illumina 2024 Annual Revenue.[1][2]
Roche is an extremely profitable company; compare the Roche and Illumina Macrotrends Retained Earnings.[3][4] Page 40 of the Roche 2024 Results presentation shows the Pharmaceuticals Division sales.[5] For Roche, the $50B investment in the U.S. makes sense, considering the current macroeconomic environment.[6]🍎🐳🏭💊💉
[1] https://www.macrotrends.net/stocks/charts/RHHBY/roche-holding-ag/cash-on-hand
[2] https://www.macrotrends.net/stocks/charts/ILMN/illumina/revenue
[3] https://www.macrotrends.net/stocks/charts/RHHBY/roche-holding-ag/retained-earnings-accumulated-deficit
[4] https://www.macrotrends.net/stocks/charts/ILMN/illumina/retained-earnings-accumulated-deficit
[5] https://assets.roche.com/f/176343/x/15cb053605/irp250130-a.pdf#page=40
[6] https://www.reuters.com/business/switzerland-flexes-financial-muscle-ahead-tariff-date-washington-2025-04-23/